MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
24 val.
Dabar
Min
66.44
Max
72.57
Pajamos | -557K -36M |
|---|---|
Pardavimai | 10M 22M |
Pelnas, tenkantis vienai akcijai | -1.29 |
Pelno marža | -165.447 |
Darbuotojai | 63 |
EBITDA | 10M -19M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +82.16% upside |
Kitas uždarbis | 2026-05-07 |
|---|
Rinkos kapitalizacija | 198M 2.1B |
|---|---|
Ankstesnė atidarymo kaina | 61.57 |
Ankstesnė uždarymo kaina | 71.9 |
By Trading Central
Pasitikėjimas
Strong Bearish Evidence
0.5949 / 0.7406 Palaikymas ir pasipriešinimas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
2026-03-31 23:31; UTC
Stocks to Watch: Nike, RH, NCino
DJ
Skaityti
2026-03-31 22:35; UTC
Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update
DJ
Skaityti
2026-04-01 00:00; UTC
The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ
DJ
Skaityti
2026-03-31 23:50; UTC
Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO
DJ
Skaityti
2026-03-31 23:43; UTC
Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk
DJ
Skaityti
2026-03-31 23:33; UTC
Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk
DJ
Skaityti
2026-03-31 23:21; UTC
Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com
DJ
Skaityti
2026-03-31 23:14; UTC
Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk
DJ
Skaityti
2026-03-31 23:12; UTC
Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke 2025 Loss Widens >000002.SZ
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ
DJ
Skaityti
2026-03-31 21:46; UTC
Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ
DJ
Skaityti
2026-03-31 21:36; UTC
West African Resources's Costs Higher Than Bull Expected -- Market Talk
DJ
Skaityti
2026-03-31 21:35; UTC
Nike Expects China Sales Down 20% in 4Q, CFO Says
DJ
Skaityti
2026-03-31 21:35; UTC
Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says
DJ
Skaityti
2026-03-31 21:35; UTC
Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says
DJ
Skaityti
2026-03-31 21:33; UTC
Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com
DJ
Skaityti
2026-03-31 21:33; UTC
Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says
DJ
Skaityti
2026-03-31 21:32; UTC
Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says
DJ
Skaityti
2026-03-31 21:28; UTC
Nike Expects to End 4Q With Elevated Inventory, CFO Says
DJ
Skaityti
2026-03-31 21:26; UTC
Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says
DJ
Skaityti
2026-03-31 21:25; UTC
Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says
DJ
Skaityti
2026-03-31 21:24; UTC
Nike: Turnaround Plan Progressing at Different Rates -- Market Talk
DJ
Skaityti
2026-03-31 21:22; UTC
Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters
DJ
Skaityti
2026-03-31 21:22; UTC
Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says
DJ
Skaityti
2026-03-31 21:21; UTC
Nike's Digital Channel Still Too Promotional, CFO Says
DJ
Skaityti
2026-03-31 21:20; UTC
Nike CEO: Converse Remains Important to Portfolio
DJ
Skaityti
Kainos pokytis
By TipRanks
12 mėnesių prognozė
Vidutinis 118.86 USD 82.16%
Aukščiausias 165 USD
Žemiausias 68 USD
Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Nektar Therapeutics kainas – Dist per pastaruosius 3 mėnesius.
By TipRanks
Stiprus pirkimas
8 ratings
7
Pirkti
1
Laikyti
0
Parduoti
Remiantis 8 analitikų, pateikusių Nektar Therapeutics akcijų reitingus – Dist per pastaruosius 3 mėnesius.
By Trading Central
Trumpalaikis periodas
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Vidutinės trukmės periodas
Strong Bearish Evidence
All events are bearish.
Ilgalaikis periodas
Bearish Evidence
All events are bearish.
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$